{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"Number of unique patients who had a treatment-related (possible, probable or definite) adverse events that were graded 3 or higher.","groups":[{"description":"All patients will receive Melphalan 100 mg/m2 intravenously day -2 and day -1 and Lenalidomide 150 mg given daily day -7 to day +2","id":"OG000","title":"Phase II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Phase II patients who received treatment.","reportingStatus":"POSTED","timeFrame":"up to 5 years","title":"Phase II: Treatment-Related Adverse Events Grade 3 or Higher","type":"SECONDARY","unitOfMeasure":"Participants"}